Zealand Pharma

Report Publication Announcement • Dec 10, 2018

Financial calendar for Zealand Pharma in 2019

Financial calendar for Zealand Pharma in 2019

Company announcement – No. 30/2018

Financial calendar for Zealand Pharma in 2019

Copenhagen, December 10, 2018 – Zealand Pharma A/S (“ZEAL”) announces the following dates for the company's planned financial reporting in 2019:

7 March                              Full year announcement and Annual Report 2018       

16 May                                Interim report for the first three months of 2019

15 August                           Interim report for first half 2019

14 November                      Interim report for the first nine months of 2019

Zealand's Annual General Meeting will be held on April 4, 2019.

For further information, please contact:

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma. 

Attachment

• 30-18_1210 Zealand Pharma Financial Calender 2019